Charles Schwab Investment Management Inc. Lowers Stock Position in Qiagen N.V. $QGEN

Charles Schwab Investment Management Inc. reduced its stake in Qiagen N.V. (NYSE:QGEN) by 67.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 60,091 shares of the company’s stock after selling 124,875 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Qiagen were worth $2,413,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of QGEN. ANTIPODES PARTNERS Ltd purchased a new position in shares of Qiagen during the first quarter worth approximately $94,000. Tower Research Capital LLC TRC grew its holdings in shares of Qiagen by 770.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 2,490 shares of the company’s stock worth $111,000 after purchasing an additional 2,204 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Qiagen by 93.9% in the first quarter. GAMMA Investing LLC now owns 2,943 shares of the company’s stock worth $118,000 after purchasing an additional 1,425 shares during the last quarter. Federated Hermes Inc. bought a new position in shares of Qiagen in the first quarter worth approximately $150,000. Finally, Wealth Enhancement Advisory Services LLC bought a new position in shares of Qiagen in the fourth quarter worth approximately $202,000. 70.00% of the stock is owned by hedge funds and other institutional investors.

Qiagen Stock Performance

Shares of Qiagen stock opened at $46.53 on Friday. The company has a current ratio of 1.61, a quick ratio of 1.35 and a debt-to-equity ratio of 0.25. The firm has a market capitalization of $10.34 billion, a P/E ratio of 27.49, a P/E/G ratio of 2.44 and a beta of 0.64. The business has a fifty day simple moving average of $48.71 and a two-hundred day simple moving average of $44.14. Qiagen N.V. has a 12 month low of $37.63 and a 12 month high of $51.88.

Qiagen (NYSE:QGEN) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 EPS for the quarter, meeting the consensus estimate of $0.60. Qiagen had a return on equity of 14.77% and a net margin of 18.30%.The business had revenue of $533.54 million during the quarter, compared to analyst estimates of $523.97 million. During the same quarter last year, the firm posted $0.55 earnings per share. The company’s revenue for the quarter was up 7.7% on a year-over-year basis. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. On average, equities analysts forecast that Qiagen N.V. will post 2.26 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on QGEN. Barclays began coverage on shares of Qiagen in a report on Tuesday, June 24th. They issued an “overweight” rating and a $55.00 target price on the stock. Wall Street Zen cut shares of Qiagen from a “strong-buy” rating to a “buy” rating in a report on Monday, August 11th. Bank of America raised their target price on shares of Qiagen from $50.00 to $53.00 and gave the stock a “buy” rating in a report on Thursday, June 26th. Cowen restated a “hold” rating on shares of Qiagen in a report on Thursday, August 7th. Finally, UBS Group raised their target price on shares of Qiagen from $48.00 to $50.00 and gave the stock a “neutral” rating in a report on Thursday, August 7th. Three equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $49.69.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.